Sign in
CompletedPhase 2

Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis

Key facts

Who runs it
Xijing Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
60 people enrolled
Started
1 Oct 2023
Ended
16 Jul 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Minocycline
Record updated
14 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Diagnosis of definite autoimmune encephalitis(Graus et al 2016.)
  • Age ≥ 18 years
  • Acute or subacute onset (rapid progression of less than 3 months)
  • Reasonable exclusion of alternative causes
  • Written informed consent

Who cannot take part

  • Uncontrolled serious concomitant illness
  • Known allergy to tetracycline antibiotics
  • Known chronic kidney disease stages 3b-5
  • Moderate liver disease (see Child-Pugh for Classification of Severity of Liver Disease)
  • history of cognitive impairment
  • Pregnant women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Autoimmune encephalitis (AE) is an immune-mediated brain disorder characterized by varied clinical manifestations that correlate with specific types of antibodies.Typical symptoms include acute behavioral changes, psychosis, seizures, memory deficits, dyskinesias, speech impairments, and autonomic and respiratory dysregulation.While the majority of patients respond well to immunotherapeutic agents, a significant proportion remains resistant to initial and secondary-line immunotherapies.Minocycline, a semisynthetic tetracycline, is notably used for the central nervous system due to its lipophilic characteristics and its capacity to penetrate the blood-brain barrier. While the primary neuroprotective focus of minocycline in the central nervous system remains unknown, the primary effects of minocycline include the inhibition of microglial activation, mitigation of apoptosis, and reduction in reactive oxygen species generation.Protective effect has been observed in hypoxic injury, ischemic stroke, amyotrophic lateral sclerosis, traumatic spinal cord injury, multiple sclerosis, Parkinson's disease, and Huntington's disease.Can minocycline offer a protective role in AE? Consequently, we proposed a randomized, controlled trial to investigate the efficacy of minocycline in AE.

The 2 groups in the trial

  • Experimental: Treatment groupTreatment being tested

    Drug: Minocyclin 200 mg oral minocycline for a total of 30 days

    Treatment: Minocycline

  • Control groupNo study treatment, for comparison

    first-line drugs for autoimmune encephalitis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis: Open-lable, Randomised, Proof of Concept Study
Publications
Record updated
14 August 2025